Novartis Ag (NVS) Non-cash Items (2009 - 2026)
Novartis Ag (NVS) posted Non-cash Items of $3.4 billion for Q2 2026, up 14.32% sequentially from $3.0 billion in Q2 2025, and up 14.32% YoY from $3.0 billion in Q2 2025.
Novartis Ag (NVS) Non-cash Items (2009 - 2026) Analysis & Trends
Novartis Ag has reported Non-cash Items for 15 years, with the latest figure at $3.4 billion in Q2 2026.
- Quarterly Non-cash Items rose 14.32% year-over-year to $3.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.6 billion (up 6.32% YoY) and the FY2025 annual result came in at $11.2 billion, up 9.74% from the prior year.
- Non-cash Items improved to $3.4 billion in Q2 2026 per NVS's latest filing, from $3.0 billion in the prior quarter.
- Over five years, Non-cash Items peaked at $4.9 billion in Q4 2024 and troughed at $2.4 billion in Q2 2024.
- A 5-year average of $3.2 billion and a median of $3.0 billion in 2022 frame the typical range for Non-cash Items.
- The sharpest annual moves came in 2022 and 2023: Non-cash Items jumped 61.11% in 2022, then retreated 16.14% in 2023.
- Over 5 years, Non-cash Items stood at $3.1 billion in 2022, then retreated by 16.14% to $2.6 billion in 2023, then jumped by 90.77% to $4.9 billion in 2024, then sank by 39.68% to $3.0 billion in 2025, then rose by 14.32% to $3.4 billion in 2026.
- According to Business Quant data, Non-cash Items over the past three periods registered $3.4 billion, $3.0 billion, and $4.9 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.38 Bn |
| Jun 30, 2026 | 3.38 Bn |
| Jun 30, 2025 | 2.95 Bn |
| Jun 30, 2025 | 2.95 Bn |
| Dec 31, 2024 | 4.90 Bn |
| Dec 31, 2024 | 4.90 Bn |
| Jun 30, 2024 | 2.40 Bn |
| Jun 30, 2024 | 2.40 Bn |
| Jun 30, 2023 | 2.57 Bn |
| Jun 30, 2023 | 2.57 Bn |
| Jun 30, 2022 | 3.06 Bn |
| Jun 30, 2022 | 3.06 Bn |
| Jun 30, 2021 | 1.90 Bn |
| Jun 30, 2021 | 1.90 Bn |
| Jun 30, 2020 | 2.35 Bn |
| Jun 30, 2020 | 2.35 Bn |
| Jun 30, 2019 | 2.09 Bn |
| Jun 30, 2019 | 2.09 Bn |
| Dec 31, 2018 | 2.35 Bn |
| Dec 31, 2018 | 2.35 Bn |